MedTrace Logo

The Expression of Serum Angiogenesis Marker in Patients Presenting With Hemoptysis

NCT01171768 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 52

Last updated 2011-07-21

No results posted yet for this study

Summary

Vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang-2) are major mediators of angiogenesis and are induced by tissue inflammation and hypoxia. While elevated serum VEGF levels have been reported in inflammatory lung diseases, especially with hemoptysis, there was no study to evaluate the Ang-2 levels in lung inflammatory diseases according to the presence of hemoptysis, inflammatory biomarker and hypoxia.

Conditions

  • Inflammatory Lung Diseases
  • Hemoptysis

Sponsors & Collaborators

  • Samsung Medical Center

    lead OTHER

Eligibility

Min Age
20 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-06-30
Completion
2010-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01171768 on ClinicalTrials.gov